Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on improving medication adherence and patient outcomes in chronic disease management [1][3]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company specializing in miniature, ultra long-acting drug implants [1][3]. - The company utilizes its proprietary NanoPortal™ technology to develop biopharmaceutical implants that deliver drug molecules steadily over extended periods [3]. - Medication non-adherence affects approximately 50% of patients, highlighting the need for innovative solutions [3]. Product Pipeline - The priority product candidate is NPM-139, a miniature, six-month, subdermal GLP-1 (semaglutide) implant aimed at chronic weight management in obese or overweight individuals [3]. - NPM-139 has the potential for once-yearly dosing, which could significantly enhance patient compliance [3]. - Other products in development include NPM-115 (exenatide implant) for chronic weight management and NPM-119 (exenatide implant) for type-2 diabetes treatment [3]. Upcoming Presentation Details - CEO Adam Mendelsohn will present on September 10, 2025, at the Lotte New York Palace Hotel, focusing on the company's innovative drug implant technology [1]. - The presentation is part of the H.C. Wainwright 27th Annual Global Investment Conference, which runs from September 8-10, 2025 [1].